---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-036999"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:08:39.717741+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corcept Q2 revenue rises 19% to $194.4M; 2025 guidance raised to $850-900M

## Summary
- Revenue $194.4M (+19% YoY); net income $35.1M vs $35.5M; diluted EPS $0.29 vs $0.32.
- Modified 2025 revenue guidance to $850-900M; cash & investments $515M after $115.4M buyback.
- NDA for relacorilant in hypercortisolism (PDUFA Dec 30, 2025); NDA submitted for ovarian cancer.
- DAZALS: dazucorilant 300mg showed 84% reduced death risk (HR 0.16, p=0.0009); regulatory discussions.
- Record new prescribers/patients; vendor capacity constraints offset demand; second pharmacy coming online.

## SEC filing metadata
- accession: 0001628280-25-036999
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828025036999/0001628280-25-036999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828025036999/cort-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-036999
- JSON: https://secwatch.observer/filing/0001628280-25-036999.json
- Plain text: https://secwatch.observer/filing/0001628280-25-036999.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.